High-Impact Form 4 Intelligence
Real-time SEC insider trading data with advanced filtering. Free beta.
Total Buys (Filtered)
$0
$0
Total Sells (Filtered)
$66.8M
$66,796,358
| Ticker | Company | Reporting Owner | Date | Value (USD) | Type | Form 4 |
|---|---|---|---|---|---|---|
|
BBIO
S
BridgeBio Pharma, Inc.
Ellis Andrea
• Director
10b5-1 SellΔOwn -77.7%
2026-03-04
$4,211,302Large
|
||||||
| BBIO |
BridgeBio Pharma, Inc.
|
Director
10b5-1 SellΔOwn -77.7%
|
2026-03-04 | $4,211,302Large | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
Director
Other
|
2026-03-04 | $548,582 | M | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
Director
Other
|
2026-02-27 | $1,234,700Large | M | Form 4 |
|
BBIO
S
BridgeBio Pharma, Inc.
Valantine Hannah
• Director
10b5-1 SellΔOwn -44.3%
2026-02-27
$978,285
|
||||||
| BBIO |
BridgeBio Pharma, Inc.
|
Director
10b5-1 SellΔOwn -44.3%
|
2026-02-27 | $978,285 | S | Form 4 |
|
BBIO
S
BridgeBio Pharma, Inc.
Valantine Hannah
• Director
10b5-1 SellΔOwn -59.4%
2026-02-27
$739,496
|
||||||
| BBIO |
BridgeBio Pharma, Inc.
|
Director
10b5-1 SellΔOwn -59.4%
|
2026-02-27 | $739,496 | S | Form 4 |
|
BBIO
S
BridgeBio Pharma, Inc.
Apuli Maricel
• Officer • Chief Accounting Officer
10b5-1 Sell
2026-02-26
$132,000
|
||||||
| BBIO |
BridgeBio Pharma, Inc.
|
Officer • Chief Accounting Officer
10b5-1 Sell
|
2026-02-26 | $132,000 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2026-02-19 | $614,702 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2026-02-19 | $1,344,190Large | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2026-02-19 | $43,826 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
Director
Other
|
2026-02-17 | $167,500 | M | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
Director
10b5-1 SellΔOwn -24.3%
|
2026-02-17 | $362,219 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
Director
10b5-1 SellΔOwn -22.2%
|
2026-02-17 | $251,088 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CFO
10b5-1 Sell
|
2026-02-17 | $1,001,071Large | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CFO
10b5-1 Sell
|
2026-02-17 | $15,076 | S | Form 4 |
|
BBIO
S
BridgeBio Pharma, Inc.
Apuli Maricel
• Officer • Chief Accounting Officer
10b5-1 Sell
2026-02-17
$37,898
|
||||||
| BBIO |
BridgeBio Pharma, Inc.
|
Officer • Chief Accounting Officer
10b5-1 Sell
|
2026-02-17 | $37,898 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
Director
10b5-1 Sell
|
2026-02-17 | $141,250 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2026-02-11 | $290,145 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2026-02-11 | $319,938 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2026-02-11 | $269,754 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2026-02-11 | $555,706 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2026-02-11 | $292,574 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2026-02-11 | $325,695 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2026-02-11 | $265,477 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2026-02-11 | $551,796 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2026-02-10 | $1,019,657Large | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2026-02-10 | $1,008,006Large | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2026-02-10 | $430,751 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2026-02-10 | $419,165 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2026-01-09 | $533,569 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2026-01-09 | $144,882 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2026-01-09 | $827,016 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2026-01-09 | $464,289 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2026-01-09 | $105,928 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2026-01-09 | $29,322 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2026-01-09 | $816,365 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2026-01-09 | $162,943 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2026-01-08 | $22,561 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2026-01-08 | $601,340 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2026-01-08 | $848,018 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2026-01-08 | $851,811 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2026-01-08 | $605,061 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2026-01-08 | $30,064 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2025-12-15 | $127,910 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 SellΔOwn -10.9%
|
2025-12-15 | $2,111,992Large | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
Equity Compensation
|
2025-12-12 | $0 | M | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2025-12-05 | $914,324 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2025-12-05 | $568,758 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2025-12-05 | $897,529 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2025-12-05 | $551,951 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2025-12-04 | $426,358 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2025-12-04 | $153,638 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2025-12-04 | $907,381 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2025-12-04 | $426,939 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2025-12-04 | $153,626 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2025-12-04 | $907,970 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2025-11-20 | $942,361 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2025-11-20 | $363,986 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2025-11-20 | $415,877 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
Director
Discretionary SellΔOwn -38.0%
|
2025-11-18 | $2,047,057Large | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
Director
Discretionary SellΔOwn -22.7%
|
2025-11-18 | $1,566,013Large | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
Director
Discretionary SellΔOwn -67.3%
|
2025-11-17 | $2,451,914Large | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
Director
Discretionary SellΔOwn -21.2%
|
2025-11-17 | $254,679 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
Director
10b5-1 SellΔOwn -34.9%
|
2025-11-17 | $414,656 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
Director
10b5-1 SellΔOwn -17.6%
|
2025-11-17 | $251,809 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
Director
Other
|
2025-11-17 | $167,500 | M | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CFO
10b5-1 Sell
|
2025-11-17 | $464,938 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CFO
10b5-1 Sell
|
2025-11-17 | $660,467 | S | Form 4 |
|
BBIO
S
BridgeBio Pharma, Inc.
Valantine Hannah
• Director
Discretionary SellΔOwn -77.3%
2025-11-12
$1,683,728Large
|
||||||
| BBIO |
BridgeBio Pharma, Inc.
|
Director
Discretionary SellΔOwn -77.3%
|
2025-11-12 | $1,683,728Large | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
Director
Other
|
2025-11-12 | $1,234,700Large | M | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2025-11-07 | $763,762 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2025-11-07 | $13,815 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2025-11-07 | $12,561 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2025-11-07 | $747,862 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2025-11-07 | $466,839 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2025-11-07 | $452,156 | S | Form 4 |
|
BBIO
S
BridgeBio Pharma, Inc.
DANIELS RONALD J
• Director
Discretionary SellΔOwn -78.2%
2025-11-06
$3,888,999Large
|
||||||
| BBIO |
BridgeBio Pharma, Inc.
|
Director
Discretionary SellΔOwn -78.2%
|
2025-11-06 | $3,888,999Large | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2025-11-06 | $468,472 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2025-11-06 | $788,184 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2025-11-06 | $6,439 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2025-11-06 | $465,416 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2025-11-06 | $791,166 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
Director
Other
|
2025-11-06 | $2,114,724Large | M | Form 4 |
|
BBIO
S
BridgeBio Pharma, Inc.
MCCORMICK FRANK
• Director
10b5-1 SellΔOwn -12.7%
2025-10-29
$7,317,315Whale
|
||||||
| BBIO |
BridgeBio Pharma, Inc.
|
Director
10b5-1 SellΔOwn -12.7%
|
2025-10-29 | $7,317,315Whale | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
Director
10b5-1 Sell
|
2025-10-29 | $3,004,349Large | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
Director
10b5-1 Sell
|
2025-10-29 | $588,985 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
Director
10b5-1 Sell
|
2025-10-29 | $236,130 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
Director
10b5-1 Sell
|
2025-10-29 | $2,059,749Large | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
Director
10b5-1 Sell
|
2025-10-27 | $106,665 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2025-10-09 | $1,096,046Large | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2025-10-08 | $622,171 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2025-10-08 | $473,504 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2025-10-08 | $473,450 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2025-10-08 | $622,226 | S | Form 4 |